Stay updated with breaking news from Nasdaq Immx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Immix Biopharma, Inc. (NASDAQ:IMMX – Get Rating) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 146,500 shares, a growth of 24.3% from the February 28th total of 117,900 shares. Based on an average trading volume of 182,200 shares, the […]
Immix Biopharma, Inc. (NASDAQ:IMMX – Get Rating) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 146,500 shares, a growth of 24.3% from the February 28th total of 117,900 shares. Based on an average trading volume of 182,200 shares, the short-interest ratio is […]
Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma...
One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA...
The IMMX Milestone Day Event is viewable at www.immixbio.com/Apr2022MilestoneDayManagement discussed financial position, milestones, and new opportunities...